Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


FDA/EC/EMEA joint inspections

Executive Summary

FDA has agreed to collaborate with the European Commission and European Medicines Agency on pilot projects involving joint inspections of pharmaceutical manufacturers in the U.S. and EU and of manufacturers of active pharmaceutical ingredients in "third" countries, the Transatlantic Economic Council announced at a May 13 meeting in Brussels. The organizations will also pilot the exchange of inspection results to better identify API manufacturers in third countries and will accelerate efforts to determine "to what extent dedicated production facilities are necessary for certain pharmaceuticals," according to a TEC summary. Formed in 2007, the TEC is designed to foster closer economic standards by harmonizing standards and is comprised of U.S. Cabinet members and European commissioners

You may also be interested in...

CBER To Train Foreign Regulators On Biologics Review

October seminar is planned in response to international requests; CDER will hold companion forum.

Interview: Arvelle Aims To Be Major Player In CNS

The Swiss biotech's focal-onset seizure therapy, which is licensed from South Korea's SK and is already approved in the US, could have potential in indications beyond epilepsy, Arvelle's CEO tells Scrip.

The Factory Floor: Biocon Celebrates Malaysian Insulin Plant Clearance

Biocon has reported FDA clearance for its Malaysian insulin facility, while Lupin and Xellia have also received plant approvals. Meanwhile, Alembic has seen mixed fortunes, receiving both Form 483 observations and an EIR.




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts